who should not take glp-1 drugs Medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness Weight loss with GLP-1 medicines
Description
14 However, in two studies that included participants not enrolled in the SURPASS and SURMOUNT studies, ie, a large number of individuals who switched from other GLP-1 RAs to tirzepatide, those who transitioned from semaglutide experienced greater weight loss with tirzepatide treatment
In June 2025, MBX Biosciences announced that it has submitted an IND application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug targeting obesity, which received regulatory clearance in July
Early results show reductions in cravings, substance use, and other related outcomes
Insulin inhibits glucagon secretion by the activation of PI3-kinase in In-R1-G9 cells
